Grifols SA
MAD:GRF

Watchlist Manager
Grifols SA Logo
Grifols SA
MAD:GRF
Watchlist
Price: 9.306 EUR -0.39% Market Closed
Market Cap: 6.3B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GRF stock under the Base Case scenario is 28.69 EUR. Compared to the current market price of 9.306 EUR, Grifols SA is Undervalued by 68%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GRF Relative Value
Base Case
28.69 EUR
Undervaluation 68%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.9
P/S
P/S
Price to Sales
0.9
vs History
84
vs Industry
87
Median 3Y
1
Median 5Y
1.3
Industry
6.9
Forward
0.8
More Details
40.4
P/E
P/E
Price to Earnings
40.4
vs History
28
vs Industry
4
Median 3Y
37.9
Median 5Y
33
Industry
22.9
Forward
11.9
More Details
7
P/OCF
P/OCF
Price to OCF
7
vs History
53
vs Industry
14
Median 3Y
10
Median 5Y
7.9
Industry
19.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-14.1
Median 5Y
-9.3
Industry
23.5
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
79
vs Industry
58
Median 3Y
1.2
Median 5Y
1.4
Industry
2.5
More Details
1.9
EV/S
EV/S
Enterprise Value to Sales
1.9
vs History
84
vs Industry
67
Median 3Y
2.2
Median 5Y
2.7
Industry
7.4
Forward
1.8
More Details
4.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.9
vs History
84
vs Industry
56
Median 3Y
5.8
Median 5Y
7.2
Industry
9.1
More Details
8.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.7
vs History
92
vs Industry
12
Median 3Y
14.3
Median 5Y
12.6
Industry
3.8
Forward
7.1
More Details
11.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.9
vs History
92
vs Industry
10
Median 3Y
17.4
Median 5Y
20.2
Industry
3.8
Forward
9.6
More Details
15.3
EV/OCF
EV/OCF
Enterprise Value to OCF
15.3
vs History
36
vs Industry
11
Median 3Y
15.8
Median 5Y
14.3
Industry
4.9
More Details
26
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
26
vs History
20
vs Industry
6
Median 3Y
-75.8
Median 5Y
11.9
Industry
3.5
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
82
vs Industry
61
Median 3Y
0.8
Median 5Y
0.9
Industry
4.6
More Details

Multiples Across Competitors

GRF Competitors Multiples
Grifols SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Grifols SA
MAD:GRF
6.3B EUR 0.9 40.4 8.7 11.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 170 874.7 -167 162 -202 987.9 -200 671.6
US
Abbvie Inc
NYSE:ABBV
323.7B USD 5.6 77.9 14.9 22
US
Amgen Inc
NASDAQ:AMGN
146.1B USD 4.3 24.6 13.5 22.2
US
Gilead Sciences Inc
NASDAQ:GILD
133.7B USD 4.7 22.4 9.8 13.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112B USD 10.1 -113.3 24 25.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 003.1 -511.1 -556.6 -541.7
AU
CSL Ltd
ASX:CSL
119.3B AUD 5.1 28.2 17.4 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
63.7B USD 4.5 14.1 12.7 14.3
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.7 -57.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
37.8B USD 16.1 -140.1 -625.8 -313.6
P/S Multiple
Revenue Growth P/S to Growth
ES
Grifols SA
MAD:GRF
Average P/S: 3 197 540.8
0.9
7%
0.1
FR
Pharnext SCA
OTC:PNEXF
35 170 874.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 003.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
5%
0.9
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
29%
0.6
P/E Multiple
Earnings Growth PEG
ES
Grifols SA
MAD:GRF
Average P/E: 34.6
40.4
74%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 162 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.4
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -113.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.1 N/A N/A
AU
CSL Ltd
ASX:CSL
28.2
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.1
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -140.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Grifols SA
MAD:GRF
Average EV/EBITDA: 14.4
8.7
15%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 987.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.7
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -625.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Grifols SA
MAD:GRF
Average EV/EBIT: 18.7
11.9
17%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 671.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.5
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -541.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.3
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313.6 N/A N/A

See Also

Summary
GRF intrinsic value, competitors valuation, and company profile.
DCF Valuation
GRF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GRF stock valuation using valuation multiples.
Wall Street Estimates
GRF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GRF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 256,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.